Oragenics Inc is a biotechnology company focused on the development of innovative solutions for infectious diseases and oral health. The company is primarily engaged in creating novel antibiotics and therapeutics, particularly against multi-drug resistant pathogens, as well as products aimed at enhancing oral health through advanced microbial therapies. Oragenics leverages its proprietary technologies and research capabilities to address significant medical needs, with a mission to improve patient outcomes and combat rising antibiotic resistance through targeted and effective treatment options. Read More
Oragenics (NYSE American: OGEN) a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, has closed its public offering of Series H Convertible Preferred Stock and Warrants, raising approximately $16.5 million in gross proceeds. The Company sold 660,000 units—each comprising one share of Series H Convertible Preferred Stock and one Warrant—at $25.00 per unit. The Warrants, exercisable immediately at the same price, could yield an additional $16.5 million if fully exercised. Net proceeds will fund clinical development of ONP-002 for concussion, repay a $3 million bridge note, and support R&D and general operations. Dawson James Securities acted as sole placement agent.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Oragenics (NYSE American: OGEN) a developer of intranasal pharmaceuticals for neurological disorders, has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, priced at $25.00 per unit. Each Warrant allows purchase of an additional Preferred share at $25.00, with Preferred shares convertible into common stock at $2.50. Gross proceeds could total $20 million, which will support ONP-2 concussion trials, R&D, repayment of a $3 million bridge note, and general corporate needs. Dawson James Securities, Inc. is acting as sole placement agent, with closing expected on or about July 2, 2025.
Oragenics (NYSE American: OGEN) announced that Head of Business Development Greg Gironda will present at the 2025 BIO International Convention from June 16–19 in Boston, while the company also attends the 42nd Annual National Neurotrauma Society Symposium from June 15–18 in Philadelphia. The events provide critical platforms to showcase ONP-002, Oragenics’ intranasal neurosteroid candidate for concussion treatment, and to connect with global leaders across neuroscience and pharmaceutical sectors.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
